The Round

Feel Peptides, a consumer peptide startup co-founded by serial entrepreneur Stephen Brudzewski and Pamela Borrero, has closed a $3 million seed round led by Sugar Capital and co-led by Hyve Ventures. The round was oversubscribed — pulling in six times the amount the founders initially targeted — and includes a roster of angel investors spanning medical, beauty, and wellness circles, among them plastic surgeon Ben Talei, makeup artist and brand founder Patrick Ta, and Four Seasons Yachts CMO Angélic Vendette.

The company is soft-launching alongside the raise, positioning itself as the brand layer for the peptide category: a direct-to-consumer platform designed to occupy the space between unlicensed gray-market sellers and expensive clinical longevity programs. Its planned membership model, inspired structurally by Costco's Executive tier, will offer annual subscribers access to pharmaceutically-sourced peptides at meaningful discounts, with a fee set between $200 and $400 per year.

The Regulatory Catalyst Nobody Wants to Miss

The timing of Feel's raise is not coincidental. Since 2023, the FDA has placed 19 peptides on a restricted list — effectively barring them from compounding pharmacy channels and pushing an already-enthusiastic consumer base into opaque online markets and unlicensed wellness clinics. That landscape is now changing. In April 2026, the FDA announced a Pharmacy Compounding Advisory Committee meeting scheduled for July 23–24, 2026, at which the agency will specifically evaluate whether compounds including BPC-157, KPV, TB-500, and MOTs-C meet the criteria for inclusion on the 503A Bulk Drug Substances List — effectively clearing a path to regulated production and consumer access.

The political current is also favorable. HHS Secretary Robert F. Kennedy Jr. has publicly signaled support for expanding access to peptide therapies, describing them as signaling molecules with legitimate therapeutic potential that consumers are already using — just without adequate safety oversight. That framing has given peptide startups a rare alignment of regulatory momentum, consumer demand, and political tailwind simultaneously.

Why Sugar Capital's Involvement Matters

Sugar Capital's lead position in this round carries weight that goes beyond the check size. The firm was an early investor in Grüns, the nutritional gummy brand founded by Chad Janis in August 2023 that was acquired by Unilever for $1.2 billion in April 2026 — a 32-month journey from first product to billion-dollar exit that stands as one of the fastest major CPG transactions on record. The Grüns playbook — consumer-first branding, subscription economics, aggressive retail distribution, and a category tailored to what people already want to do with their bodies — is directly legible in Feel's positioning.

Brian Sugar had been publicly signaling his conviction in the peptide category for months before the Feel investment closed, writing in a widely circulated blog post that peptides had moved "from lab to beauty shelf to consumer vocabulary without anyone calling a press conference" — and issuing an open call to any founder building a peptide business. The Feel investment was, in a sense, the logical culmination of that thesis.

Hyve Ventures co-lead Kara La Forgia pointed to the GLP-1 trajectory as the directional proof point: two peptides generated more consumer revenue in 2025 than the world's two most prominent AI companies combined. The analogy is deliberately provocative, but it makes a structurally serious point — when a peptide-based product solves a biological problem consumers viscerally experience, the adoption curve can be extraordinarily steep.

The Competitive Landscape: Protocole and the Race to Infrastructure

Feel is not operating in a vacuum. In April 2026, Protocole — co-founded by Delphine Le Grand and Cindy Yan, both veterans of the longevity space — emerged from stealth with a $6 million seed round led by Rare Capital. Where Feel is building a consumer brand with membership economics, Protocole is building clinical infrastructure: physician-guided protocols, regulated pharmacy fulfillment, and a referral-only membership model that prices access at $60 per month for ongoing clinical oversight (peptides sold separately).

The two companies represent divergent strategic bets on how the regulated peptide market will ultimately stratify. Feel is building for scale and brand accessibility — a Costco-style membership that democratizes pharmaceutical-grade peptides for a mass wellness audience. Protocole is building for credibility and clinical rigor — a concierge model targeting consumers who want physician oversight and structured care pathways, not just a subscription box.

Both theses are plausible and potentially complementary. Consumer health categories frequently bifurcate between clinical-grade and consumer-accessible tiers once regulatory clarity arrives, with distinct price points, acquisition channels, and lifetime value profiles. The real question is whether the FDA's July ruling will open the floodgates broadly enough to support multiple scaled players — or whether the first mover with the clearest brand claim will disproportionately capture the category.

What the Gray Market Collapse Actually Means

Understanding the opportunity requires understanding what currently exists. The majority of consumer peptide demand today is served through compounding pharmacies operating in regulatory gray zones, online sellers with minimal quality or purity transparency, and wellness clinics where sourcing standards vary widely. This is not a niche phenomenon: consumer interest in peptides for recovery, longevity, metabolic health, and cognitive performance has grown substantially in the wake of GLP-1 drug adoption, as consumers who experienced measurable biological change on Ozempic or Wegovy began actively asking what else peptide science could offer.

The gray market's structural weakness is its ceiling. Without regulatory legitimacy, distribution is constrained to direct-to-consumer online channels and clinical settings. Retail placement, mainstream media advertising, employer wellness programs, and health insurance integration are all effectively inaccessible. The moment the FDA provides reclassification — moving targeted peptides from restricted status to regulated compounding eligibility — those distribution channels unlock simultaneously, and the total addressable market expands by orders of magnitude. That is the bet Feel and Protocole are making: be positioned before the gate opens.

Implications for MENA's Functional Wellness Sector

The peptide category may appear US-centric at first glance — the regulatory action is unfolding at the FDA, and the founding teams are operating out of American consumer markets. But for food and wellness operators across Saudi Arabia and the wider MENA region, there are several reasons to track this development closely.

GLP-1 medications have already reshaped Gulf consumer behavior meaningfully. Semaglutide and tirzepatide prescriptions have grown substantially across Saudi Arabia and the UAE, driven by high rates of obesity and metabolic disease and a healthcare ecosystem increasingly open to novel therapies. That consumer base — already biologically curious, already comfortable with injectable wellness protocols, and already paying premium prices for health outcomes — is precisely the cohort that will be receptive to the next layer of peptide-based products once regulatory legitimacy and brand clarity arrive.

Vision 2030's emphasis on preventive health, the expansion of Saudi Arabia's private health sector, and the growing sophistication of Gulf consumers on functional nutrition and longevity all create conditions where a well-branded, medically credible peptide platform could find meaningful adoption. The distribution pathway is less direct than in the US — regional regulatory frameworks would need to evolve in parallel with FDA action — but the consumer demand signal is already present.

For regional food and beverage operators, the more immediate implication is brand positioning: the functional wellness space is becoming increasingly sophisticated, and the companies that build early credibility around science-backed health claims — whether in gummies, beverages, meal replacements, or injectable formats — will be better positioned to capture the consumer segment that GLP-1 adoption has primed.

Editorial View

Feel Peptides' $3 million raise is, by the numbers, a small seed round. But its significance lies in what it signals about investor conviction and timing. Sugar Capital is not dabbling — the firm backed Grüns when gummy supplements looked like a crowded market, and the exit validated a thesis that a great consumer brand could define a category even when the science predated the brand by years. The same logic applies here with considerably more regulatory tailwind.

The real story in the peptide space is not any individual company — it is the structural transition from a gray market to a regulated consumer category. When that transition completes, it will generate winners across brand, clinical infrastructure, pharmacy fulfillment, and formulation technology. The investors currently writing $3M to $6M seed checks are not buying the current market. They are buying the category that emerges when the FDA acts, the brands gain shelf space, and the hundred million consumers already oriented toward biological self-optimization have a legitimate place to spend.

For MENA health and wellness strategists, the lesson is both directional and urgent: GLP-1 adoption has demonstrated that Gulf consumers are ahead of their regional regulatory environment. Peptides may be next — and the brand equity positions will be claimed early.